GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Net Income From Continuing Operations

Australian Clinical Labs (ASX:ACL) Net Income From Continuing Operations : A$15.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Australian Clinical Labs's net income from continuing operations for the six months ended in Dec. 2023 was A$5.1 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was A$15.6 Mil.

Australian Clinical Labs Net Income From Continuing Operations Historical Data

The historical data trend for Australian Clinical Labs's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Net Income From Continuing Operations Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
Net Income From Continuing Operations
- 60.39 178.40 36.04

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial 130.29 48.11 25.48 10.56 5.08

Australian Clinical Labs Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$15.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australian Clinical Labs (ASX:ACL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Net Income From Continuing Operations
Comparable Companies
ASX:MVF ASX:IDX ASX:MAP ASX:GSS ASX:IIQ ASX:RHY ASX:HLS ASX:LDX ASX:CTE ASX:GTG TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH
Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Website
https://www.clinicallabs.com.au
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines